Shares of NeoGenomics Inc. (NEO) are up over 24% at $8.93 in premarket trading on Friday, following a favorable ruling in a patent infringement lawsuit against Natera Inc. (NTRA).
NeoGenomics offers a wide range of oncology diagnostic testing assays and consultative services - one of which is its RaDaR. The RaDaR assay is a personalized, tumor-informed, highly sensitive technology that tracks a set of up to 48 tumor-specific variants in cell-free DNA (cfDNA) within a cancer patient's blood plasma.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.